Monday, May 7, 2007

Vivo Ventures Closes $275M Life Science Venture Fund

Palo Alto-based Vivo Ventures has closed a $275M life sciences venture fund, Vivo Ventures Fund VI, L.P., the firm said this morning. The fund continues to follow the same general approach as the firm's prior funds, and is focused on companies developing and commercializing therapeutic products. The new fund will be managed by Frank Kung, Edgar Engleman and Albert Cha. Institutional investors in the fund were not disclosed.